- Current report filing (8-K)
October 28 2010 - 6:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 28, 2010
SHENGTAI
PHARMACEUTICAL, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.07.
|
Submission
of Matters to a Vote of Security
Holders.
|
The 2010
annual general meeting of stockholders of Shengtai Pharmaceutical, Inc. (the
“Company”) was held on October 26, 2010. The following matters were
voted upon:
|
1.
|
The
election of five directors to serve a one-year term expiring at the 2011
annual general meeting of stockholders and until their successors have
been elected and qualified.
|
The five
nominees were elected as directors, by the following votes (with 3,125,536
Broker Non-Votes):
Nominee
|
|
For
|
|
Against
|
|
Abstentions
|
Qingtai
LIU
|
|
11,770,733
|
|
3,250
|
|
90,731
|
Yongqiang
WANG
|
|
11,487,313
|
|
348,901
|
|
28,500
|
Winfred
LEE
|
|
11,487,313
|
|
348,901
|
|
28,500
|
Yaojun
LIU
|
|
11,770,733
|
|
3,250
|
|
90,731
|
Fei
HE
|
|
11,832,964
|
|
3.250
|
|
28,500
|
|
2.
|
The
authorization to the Company’s Board of Directors to effect a reverse
stock split of issued and outstanding shares of the Company’s Common Stock
at a 1 for 2 ratio and, if and when the reverse stock split is effected,
to reduce the number of the Company’s authorized shares of Common Stock
and Preferred Stock by the same reverse stock split ratio and file any
required amendment to the Company’s Amended and Restated Certificate of
Incorporation to effect the same.
|
The
reverse stock split and the reduction of the Company’s authorized shares of
Common Stock and Preferred Stock by the same reverse stock split ratio and the
filing of an amendment to the Company’s Amended and Restated Certificate of
Incorporation to effect the same were approved by the following vote (with 1,000
Abstentions and 3,125,536 Broker Non-Votes):
Matter
|
|
|
For
|
|
Against
|
Approval
of the reverse stock split and the reduction of the Company’s authorized
shares of Common Stock and Preferred Stock by the same reverse stock split
ratio and the filing of an amendment to the Company’s Amended and Restated
Certificate of Incorporation to effect the same
|
|
11,829,263
|
|
34,451
|
|
3.
|
The
approval of the appointment of Kabani & Company, Inc. to serve as the
Company’s independent registered public accounting firm for the fiscal
year ending June 30, 2011.
|
The
appointment of Kabani & Company, Inc. as the Company’s independent
registered public accounting firm for the fiscal year ending June 30, 2011, was
approved by the following vote:
Matter
|
|
|
For
|
|
Against
|
Approval
of the appointment of Kabani & Company, Inc.
|
|
11,808,208
|
|
3,182,042
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICAL, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Qingtai Liu
|
|
|
Name:
Qingtai Liu
|
|
|
Title:
Chief Executive Officer
|
|
|
|
|
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From May 2024 to Jun 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2023 to Jun 2024